372 related articles for article (PubMed ID: 17130299)
21. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
22. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
23. Autoinhibition and adapter function of Syk.
Kulathu Y; Grothe G; Reth M
Immunol Rev; 2009 Nov; 232(1):286-99. PubMed ID: 19909371
[TBL] [Abstract][Full Text] [Related]
24. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
25. Swiprosin-1/EFhd2 controls B cell receptor signaling through the assembly of the B cell receptor, Syk, and phospholipase C gamma2 in membrane rafts.
Kroczek C; Lang C; Brachs S; Grohmann M; Dütting S; Schweizer A; Nitschke L; Feller SM; Jäck HM; Mielenz D
J Immunol; 2010 Apr; 184(7):3665-76. PubMed ID: 20194721
[TBL] [Abstract][Full Text] [Related]
26. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation.
Matsubara S; Koya T; Takeda K; Joetham A; Miyahara N; Pine P; Masuda ES; Swasey CH; Gelfand EW
Am J Respir Cell Mol Biol; 2006 Apr; 34(4):426-33. PubMed ID: 16339999
[TBL] [Abstract][Full Text] [Related]
27. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
28. Syk mediates BCR- and CD40-signaling integration during B cell activation.
Ying H; Li Z; Yang L; Zhang J
Immunobiology; 2011 May; 216(5):566-70. PubMed ID: 21074890
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Bourgne C; Janel A; Berger J; Rapatel C; Tournilhac O; Hermet E; Guerci A; Lioret F; Briançon A; Bamdad M; Boiret-Dupré N; Berger MG
Leuk Res; 2015 Mar; 39(3):329-34. PubMed ID: 25612940
[TBL] [Abstract][Full Text] [Related]
30. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
31. Inducible expression of hyperactive Syk in B cells activates Blimp-1-dependent terminal differentiation.
Hug E; Hobeika E; Reth M; Jumaa H
Oncogene; 2014 Jul; 33(28):3730-41. PubMed ID: 23955076
[TBL] [Abstract][Full Text] [Related]
32. Suboptimal B-cell antigen receptor signaling activity in vivo elicits germinal center counterselection mechanisms.
Königsberger S; Weis V; Prodöhl J; Stehling M; Hobeika E; Reth M; Kiefer F
Eur J Immunol; 2015 Feb; 45(2):603-11. PubMed ID: 25382621
[TBL] [Abstract][Full Text] [Related]
33. Spleen tyrosine kinase influences the early stages of multilineage differentiation of bone marrow stromal cell lines by regulating phospholipase C gamma activities.
Kusuyama J; Kamisono A; ChangHwan S; Amir MS; Bandow K; Eiraku N; Ohnishi T; Matsuguchi T
J Cell Physiol; 2018 Mar; 233(3):2549-2559. PubMed ID: 28786489
[TBL] [Abstract][Full Text] [Related]
34. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
36. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs.
Mouguelar VS; Coux G
Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells.
Sanderson MP; Gelling SJ; Rippmann JF; Schnapp A
Cell Immunol; 2010; 262(1):28-34. PubMed ID: 20053395
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
39. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
[TBL] [Abstract][Full Text] [Related]
40. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
